Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction

J Tromp, L. C. Steggink, D. J. Van Veldhuisen, J. A. Gietema, P. van der Meer*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

16 Citations (Scopus)

Abstract

Treatment for cancer has improved in the last decades, resulting in a significantly reduced morbidity and mortality. 1-3 Unfortunately, many systemic treatment options are associated with an increased risk of adverse cardiac effects. 4 These adverse cardiac effects have given rise to the field of cardiooncology. This review summarizes recent findings related to the pathophysiology and treatment of drug-induced cardiac dysfunction in cancer treatment and looks ahead at new developments in the field.

Original languageEnglish
Pages (from-to)481-490
Number of pages10
JournalClinical Pharmacology & Therapeutics
Volume101
Early online date10-Jan-2017
DOIs
Publication statusPublished - Apr-2017

Keywords

  • ANTHRACYCLINE-INDUCED CARDIOMYOPATHY
  • DOXORUBICIN-INDUCED CARDIOTOXICITY
  • CHEMOTHERAPY-INDUCED CARDIOTOXICITY
  • CELL-DERIVED CARDIOMYOCYTES
  • HIGH-DOSE CHEMOTHERAPY
  • CHRONIC HEART-FAILURE
  • BREAST-CANCER
  • CHILDHOOD-CANCER
  • RISK-FACTOR
  • TRASTUZUMAB CARDIOTOXICITY

Cite this